Clinical Trials on Cutaneous Leishmaniases

Total 1170 results

Gilead Sciences

Recruiting

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE)

United States, Spain, Czechia, Germany
University of Pennsylvania
Celgene Corporation

Completed

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE)

United States
Johns Hopkins University

Completed

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

Cutaneous Toxicity From ICI Therapy

United States
University of Pennsylvania

Recruiting

Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus (CLE)

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus

Subacute Cutaneous Lupus Erythematosus

Greece, Germany, Italy
National Taiwan University Hospital
National Science Council, Taiwan; National Health Research Institutes, Taiwan

Unknown

Multiphoton Laser Scanning Microscopy in Cutaneous Optical Pathology

Optical Biopsy | Cutaneous Pathology | Dermatopathology

Taiwan
Ben Chong
Daavlin Corporation

Completed

Low-dose UVA1 Radiation in Cutaneous Lupus Patients

Cutaneous Lupus Erythematosus

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Catalysis SL

Completed

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Cutaneous Melanoma, Stage II | Cutaneous Melanoma, Stage III | Malignant Cutaneous Melanoma

Cuba
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Galderma R&D

Completed

An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours (GK567)

Malodorous Infected Cutaneous Ulcer

Japan
Drugs for Neglected Diseases

Unknown

Short Course Regimens for Treatment of PKDL (Sudan)

PKDL - Post-Kala-Azar Dermal Leishmanioid

Sudan
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Lupus Erythematosus, Discoid | Lupus Erythematosus, Subacute Cutaneous

Mexico, Argentina, Australia, United States, France, Germany, Poland, Taiwan
Sanofi

Completed

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

Japan
Richard Wu
Iovance Biotherapeutics, Inc.

Active, not recruiting

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Locally Advanced Melanoma | Stage IV Melanoma | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
Immorna Biotherapeutics, Inc.

Recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

China
Immorna Biotherapeutics, Inc.

Active, not recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

United States
Peking University First Hospital

Recruiting

TreAtments and outComes in paTients With prImary CutAneous Lymphoma (TACTICAL)

Primary Cutaneous Lymphoma

China
Kyowa Kirin, Inc.

Active, not recruiting

Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, Relapsed

United States, United Kingdom, Spain, France, Italy
Fred Hutchinson Cancer Center
Amazon.com Services LLC

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditions

United States
Biogen

Completed

Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)

Systemic Lupus Erythematosus | Active Cutaneous Lupus Erythematosus

United States, Taiwan, Philippines, Argentina, Poland, Israel, Bulgaria, Serbia, Mexico, Colombia, Korea, Republic of, Thailand
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
National Cancer Institute (NCI)

Terminated

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditions

United States
Elizabeth Buchbinder, MD
Genentech, Inc.

Recruiting

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Stage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
M.D. Anderson Cancer Center
Seagen Inc.

Active, not recruiting

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Lymphoma | Mycosis Fungoides | Lymphoma, Primary Cutaneous Anaplastic Large Cell | CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma | Lymphomatoid Papulosis | Skin Lymphoma | Cutaneous Lymphomas | Hematologic Disorder

United States
Replimune Inc.
Regeneron Pharmaceuticals

Active, not recruiting

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)

Cutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma

Spain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
Kyowa Kirin Co., Ltd.

Recruiting

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

Healthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)

Japan
Northwestern University

Completed

Long-term Use of Romidepsin in Patients With CTCL

Cutaneous T-cell Lymphoma

United States
Azienda Ospedaliero, Universitaria Ospedali Riuniti

Completed

Reconstruction of Skin Substance Loss With "Micro-grafts" Obtained by Mechanical Disintegration (MG-1)

Trauma Injury | Cutaneous Ulcer

Italy
Drugs for Neglected Diseases
London School of Hygiene and Tropical Medicine; Institute of Tropical Medicine... and other collaborators

Completed

Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.

Visceral Leishmaniasis

Ethiopia
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
National Department of Health, Papua New Guinea; School of Medicine and Health...

Recruiting

Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws) (Trep-AByaws)

Yaws | Cutaneous Ulcer

Papua New Guinea
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph Node

United States
Fondazione Italiana Linfomi - ETS

Not yet recruiting

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma (FIL_MOGA)

Cutaneous T Cell Lymphoma | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | Cutaneous T-Cell Lymphoma/Sezary Syndrome

Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Malignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
M.D. Anderson Cancer Center

Completed

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of... and other collaborators

Active, not recruiting

VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Northwestern University

Terminated

The Effect Of Light On Scar Appearance

Cutaneous Scars

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Stanford University

Terminated

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Cutaneous T-cell Lymphoma | Cutaneous Lymphoma

United States
RedDress Ltd.

Recruiting

Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

Cutaneous Wounds

United States
University of California, Davis

Completed

5-0 Prolene Versus 5-0 Fast Absorbing Gut

Cutaneous Wound

Clinical Trials on Cutaneous Leishmaniases

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations